

**Mometasone Suspension Formulation**

Version 3.12      Revision Date: 16.10.2020      SDS Number: 23610-00016      Date of last issue: 13.09.2019  
Date of first issue: 21.10.2014

---

**Section 1: Identification**

Product name : Mometasone Suspension Formulation

**Manufacturer or supplier's details**

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

**Section 2: Hazard identification****GHS Classification**

Not a hazardous substance or mixture.

**GHS label elements**

Not a hazardous substance or mixture.

**Other hazards which do not result in classification**

None known.

---

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Glycerine	56-81-5	< 10
Cellulose	9004-34-6	< 10
Mometasone	83919-23-7	< 0.3

---

**Section 4: First-aid measures**

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.

---

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

Most important symptoms and effects, both acute and delayed	:	Rinse mouth thoroughly with water. None known.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

---

**Section 5: Fire-fighting measures**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.
Hazchem Code	:	3Z

---

**Section 6: Accidental release measures**

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

## Mometasone Suspension Formulation

Version 3.12      Revision Date: 16.10.2020      SDS Number: 23610-00016      Date of last issue: 13.09.2019  
Date of first issue: 21.10.2014

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Section 7: Handling and storage**

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**Section 8: Exposure controls/personal protection****Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	WES-TWA (Mist)	10 mg/m <sup>3</sup>	NZ OEL
Cellulose	9004-34-6	WES-TWA	10 mg/m <sup>3</sup>	NZ OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Essentially no open handling permitted.  
Use closed processing systems or containment technologies.  
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

**Personal protective equipment**

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

---

**Section 9: Physical and chemical properties**

Appearance	:	liquid
Colour	:	white to off-white, opaque
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	4.3 - 4.9
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available

## Mometasone Suspension Formulation

Version 3.12      Revision Date: 16.10.2020      SDS Number: 23610-00016      Date of last issue: 13.09.2019  
Date of first issue: 21.10.2014

---

Relative vapour density : No data available

Relative density : No data available

Density : 1 g/cm<sup>3</sup>

Solubility(ies)  
Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle size : Not applicable

---

**Section 10: Stability and reactivity**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Glycerine:**

Acute oral toxicity : LD<sub>50</sub> (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD<sub>50</sub> (Guinea pig): > 5,000 mg/kg

---

## Mometasone Suspension Formulation

Version 3.12      Revision Date: 16.10.2020      SDS Number: 23610-00016      Date of last issue: 13.09.2019  
Date of first issue: 21.10.2014

---

**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Mometasone:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.  
LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Glycerine:**

Species : Rabbit  
Result : No skin irritation

**Mometasone:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Glycerine:**

Species : Rabbit  
Result : No eye irritation

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

**Mometasone:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Mometasone:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Assessment : Does not cause skin sensitisation.  
Result : negative  
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Glycerine:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

Application Route: Ingestion

Result: negative

**Mometasone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Glycerine:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

**Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative



## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

**Mometasone:**

Species : Rat  
 Application Route : Inhalation  
 Exposure time : 2 Years  
 Dose : 0.067 mg/kg body weight  
 Result : negative

Species : Mouse  
 Application Route : Inhalation  
 Exposure time : 19 Months  
 Dose : 0.160 mg/kg body weight  
 Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Mometasone:**

Effects on fertility : Test Type: Fertility  
 Species: Rat  
 Application Route: Subcutaneous  
 Fertility: NOAEL: 0.015 mg/kg body weight  
 Symptoms: Reduced embryonic survival, Reduced foetal weight  
 Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development : Test Type: Embryo-foetal development  
 Species: Mouse  
 Application Route: Subcutaneous  
 Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Dermal  
 Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight  
 Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Dermal  
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
 Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development  
 Species: Rat  
 Application Route: Subcutaneous  
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
 Result: Effects on newborn

Test Type: Embryo-foetal development  
 Species: Rabbit  
 Application Route: Oral  
 Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight  
 Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**Components:****Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

**STOT - repeated exposure**

Not classified based on available information.

**Components:****Mometasone:**

Exposure routes : inhalation (dust/mist/fume)  
 Target Organs : Immune system, Liver, Kidney, Skin  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

## Mometasone Suspension Formulation

Version 3.12      Revision Date: 16.10.2020      SDS Number: 23610-00016      Date of last issue: 13.09.2019  
 Date of first issue: 21.10.2014

---

**Repeated dose toxicity****Components:****Glycerine:**

Species : Rat  
 NOAEL : 0.167 mg/l  
 LOAEL : 0.622 mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 13 Weeks

Species : Rat  
 NOAEL : 8,000 - 10,000 mg/kg  
 Application Route : Ingestion  
 Exposure time : 2 yr

Species : Rabbit  
 NOAEL : 5,040 mg/kg  
 Application Route : Skin contact  
 Exposure time : 45 Weeks

**Cellulose:**

Species : Rat  
 NOAEL :  $\geq 9,000$  mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days

**Mometasone:**

Species : Rat  
 NOAEL : 0.005 mg/kg  
 LOAEL : 0.3 mg/kg  
 Application Route : Oral  
 Exposure time : 30 d  
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog  
 LOAEL : 0.5 mg/kg  
 Application Route : Oral  
 Exposure time : 30 d  
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat  
 NOAEL : 0.00013 mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 90 d  
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog  
 NOAEL : 0.0005 mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 90 d  
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

## Mometasone Suspension Formulation

Version 3.12      Revision Date: 16.10.2020      SDS Number: 23610-00016      Date of last issue: 13.09.2019  
Date of first issue: 21.10.2014

---

**Aspiration toxicity**

Not classified based on available information.

**Components:****Mometasone:**

Not applicable

**Experience with human exposure****Components:****Mometasone:**

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

**Further information****Components:****Mometasone:**

Remarks : Dermal absorption possible

---

**Section 12: Ecological information****Ecotoxicity****Components:****Glycerine:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l  
Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l  
Exposure time: 16 h  
Method: DIN 38 412 Part 8

**Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Mometasone:**

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility

---

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l  
 Exposure time: 7 d  
 Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l  
 Exposure time: 48 h  
 Method: OECD Test Guideline 202  
 Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l  
 Exposure time: 96 h  
 Method: US-EPA OPPTS 850.1035  
 Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l  
 Exposure time: 72 h  
 Method: OECD Test Guideline 201  
 Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l  
 Exposure time: 32 d  
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.34 mg/l  
 Exposure time: 21 d  
 Method: OECD Test Guideline 211  
 Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 1,000 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209  
 Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l  
 Exposure time: 3 h  
 Test Type: Respiration inhibition  
 Method: OECD Test Guideline 209  
 Remarks: No toxicity at the limit of solubility

**Persistence and degradability****Components:****Glycerine:**

Biodegradability : Result: Readily biodegradable.  
 Biodegradation: 92 %  
 Exposure time: 30 d  
 Method: OECD Test Guideline 301D

**Cellulose:**

## Mometasone Suspension Formulation

Version 3.12      Revision Date: 16.10.2020      SDS Number: 23610-00016      Date of last issue: 13.09.2019  
Date of first issue: 21.10.2014

---

Biodegradability : Result: Readily biodegradable.

**Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)  
Method: OECD Test Guideline 111

**Bioaccumulative potential****Components:****Glycerine:**

Partition coefficient: n-octanol/water : log Pow: -1.75

**Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107.1  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

**Mobility in soil****Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

**Other adverse effects**

No data available

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**Section 14: Transport information****International Regulations****UNRTDG**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.

---

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

(Mometasone, Benzalkonium chloride)

Class : 9  
Packing group : III  
Labels : 9

**IATA-DGR**

UN/ID No. : UN 3082  
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(Mometasone, Benzalkonium chloride)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Mometasone, Benzalkonium chloride)

Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****NZS 5433**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Mometasone, Benzalkonium chloride)

Class : 9  
Packing group : III  
Labels : 9  
Hazchem Code : 3Z

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**Section 15: Regulatory information**

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

**HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard 2017

**HSW Controls**

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

**Section 16: Other information****Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average  
 NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-



## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.12	16.10.2020	23610-00016	Date of first issue: 21.10.2014

---

ment; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN